In a new interview with Direkt Studios, CEO Hanna Sjöström talks about the market preparation work before launch of the company’s medical device, Neola®, for continuous lung monitoring of preterm born babies. See the interview below (in Swedish).
The U.S. market is the company’s most important future market and the market preparation work before launch of Neola® has been initiated with the U.S. market in focus. In a new interview recorded in Direkt Studios, CEO Hanna Sjöström talks more about this.
In the interview, Hanna also talks more about building the company’s clinical network and the importance of this, not the least for the upcoming clinical studies. She also talks about the plans for the clinical study that will take place in the U.S. with preterm born infants.
See the interview below (in Swedish):